secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2026-04-24T23:59:59+00:00
Accession:  0001493152-26-018867
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 2.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Telomir Pharmaceuticals completes acquisition of TELI, consolidating global rights to Telomir-1
--------------------------------------------------------------------------------

- Acquired 100% of TELI for 34,389,710 restricted shares of Telomir common stock to former TELI shareholders.
- Bayshore Trust contributed $1 million at closing and has an option to provide up to $4 million upon IND acceptance and Phase 1/2 study start.
- Option includes $2 million for 1,492,537 shares at $1.34 per share upon FDA IND acceptance, and another $2 million for the same number of shares upon Phase 1/2 initiation.
- Transaction eliminates prior geographic fragmentation, giving Telomir full worldwide control of Telomir-1 development and commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226018867/0001493152-26-018867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226018867/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-018867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer